Mei Davide Antonio, Imberti Jacopo Francesco, Vitolo Marco, Bonini Niccolò, Casali Edoardo, Osoro Lucia, Casado-Arroyo Ruben, Boriani Giuseppe
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, 41121 Modena, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Rev Cardiovasc Med. 2025 Apr 23;26(4):36206. doi: 10.31083/RCM36206. eCollection 2025 Apr.
Electrophysiology (EP) procedures, including cardiac implantable electronic devices (CIEDs) and ablations, are widely used to manage arrhythmias and heart failure. These interventions, though effective, require substantial resources, prompting the need for systematic economic evaluations to inform healthcare decision-making.
A systematic review of studies from 2007 to 2024 was conducted in two phases. Phase one assessed trends in economic evaluations of EP procedures, analyzing 129 studies across regions and timeframes. Phase two focused on cost-effectiveness analyses of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-Ds), and atrial fibrillation (AF) ablation, examining outcomes like quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), while identifying factors influencing economic results.
EP procedures generally demonstrated favorable cost-effectiveness, particularly in high-income regions. Studies on ICDs and CRT-Ds consistently supported their economic value for patients with arrhythmias or heart failure, while AF ablation showed potential for long-term benefits, particularly when compared to medical therapies. However, results varied by region, reflecting differences in healthcare systems, costs, and patient populations.
The review highlights the overall cost-effectiveness of EP procedures in many settings but underscores the need for tailored economic evaluations in low- and middle-income countries. Simplified methodologies and greater attention to regional contexts are recommended to guide resource allocation and policy development globally.
电生理(EP)手术,包括心脏植入式电子设备(CIED)和消融术,被广泛用于治疗心律失常和心力衰竭。这些干预措施虽然有效,但需要大量资源,因此需要进行系统的经济评估,为医疗决策提供依据。
分两个阶段对2007年至2024年的研究进行了系统评价。第一阶段评估了EP手术经济评估的趋势,分析了不同地区和时间范围内的129项研究。第二阶段重点关注植入式心脏复律除颤器(ICD)、心脏再同步化治疗除颤器(CRT-D)和心房颤动(AF)消融的成本效益分析,研究质量调整生命年(QALY)和增量成本效益比(ICER)等结果,同时确定影响经济结果的因素。
EP手术总体上显示出良好的成本效益,尤其是在高收入地区。关于ICD和CRT-D的研究一致支持它们对心律失常或心力衰竭患者的经济价值,而AF消融显示出长期获益的潜力,特别是与药物治疗相比时。然而,结果因地区而异,反映了医疗系统、成本和患者群体的差异。
该综述强调了EP手术在许多情况下的总体成本效益,但强调了在低收入和中等收入国家进行针对性经济评估的必要性。建议采用简化方法并更加关注区域背景,以指导全球的资源分配和政策制定。